Trial Profile

A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study of visilizumab in subjects with intravenous steroid-refractory ulcerative colitis.

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 02 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Visilizumab (Primary)
Indications Ulcerative colitis
Focus Therapeutic Use
Sponsors PDL BioPharma

Most Recent Events

31 Aug 2024 This trial has been completed in Czechia according to European Clinical Trials Database record.
25 Sep 2009 New trial record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com